Helicobacter pylori - RECCE® 435
Helicobacter pylori (H. pylori) is the leading cause of peptic ulcers and stomach cancer worldwide. With no first-line therapy curative in all patients, H. pylori remains a significant cause of morbidity and mortality. The World Health Organization (WHO) lists H. pylori as a priority pathogen, posing as one of the greatest threats to human health.
Helicobacter pylori Cases and Fatalities by Geographical Area
- Estimated 4.4 billion worldwide (over half of the global population)
- Estimated 39.8% of population (up to 300 million people)
- Estimated up to 40% of the population (up to 131 million)
- Estimated up to 30% of the population (up to 7.6 million people)
About RECCE® 435
RECCE® 435 (R435), a broad-spectrum polymer antibiotic specifically formulated for oral use for the treatment of H. pylori infections, has the potential to address infections caused by this digestive bacterium. With more than four billion people worldwide infected with H. pylori, R435 could be the first non-combination treatment.
|Asset Route of administration||Indications||Discovery||Preclinical||Phase I||Phase II||Phase III||Next data readout||Market Size|
|R435 Oral R529||Helicobacter pylori in stomach ulcers||
||Up to 4.4 billion worldwide|